Feb 28, 2019 4:51pm EST IMV Inc. Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares
Jan 29, 2019 7:05am EST IMV Announces Clinical Update for DPX-Survivac Program in Ovarian Cancer Following Positive Feedback from U.S. FDA
Jan 17, 2019 7:05am EST First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMV’s DPX Delivery Platform in Ovarian Cancer Patients
Dec 13, 2018 4:05am EST IMV Inc. Presents Updated Positive Data From Phase 1b/2 Combination Clinical Trial in Advanced Ovarian Cancer at 2018 ESMO Immuno-Oncology Congress
Dec 10, 2018 7:05am EST IMV Announces Updated Clinical Data Presentation for Lead Candidate DPX-Survivac’s Phase 1b/2 Immunotherapy Combination Trial at the ESMO Immuno-Oncology Congress 2018
Dec 05, 2018 7:05am EST IMV Welcomes Marc Jasmin as Senior Director, Investor Relations and Communications
Nov 26, 2018 4:35pm EST IMV Leadership to Present Respiratory Syncytial Virus (RSV) Research at RespiDART 2018
Nov 20, 2018 7:05am EST IMV Moves to Develop DPX-Survivac as Monotherapy for Recurrent Ovarian Cancer
